Abstract
Benign uterine leiomyoma (U.LMA) and malignant uterine leiomyosarcoma (U.LMS), which are both uterine mesenchymal tumors, are distinguished by the number of cells with mitotic activity. However, uterine mesenchymal tumors contain tumor cells with various cell morphologies; therefore, making a diagnosis, including differentiation between benign tumors and malignant tumors, is difficult. For example, uterine smooth muscle tumors of uncertain malignant potential (STUMPs) are a group of uterine mesenchymal tumors for which performing a differential diagnosis is challenging. A standardized classification system for uterine mesenchymal tumors has not yet been established. Furthermore, definitive preoperative imaging techniques or hematological examinations for the potential inclusion of STUMP in the differential diagnosis have not been defined. Several clinical studies showed that there is no correlation between biomarker expression and mitotic rate or tumor recurrence. The current immunohistochemical biomarkers cannot effectively help determine the malignant potential of STUMPs in patients who wish to become pregnant in the future. The establishment of gene expression profiles or detection of pathogenic variants by employing next-generation molecular techniques can aid in disease prediction, diagnosis, treatment, and prognosis. Here, we describe the problems in diagnosing uterine mesenchymal tumors along with the results of the latest clinical studies.
Reference13 articles.
1. Lin YM, Hong SY, Teng SW, Chang CK, Lai TJ. Retrospective Analysis on Characteristics of Uterine Smooth Muscle Tumors of Uncertain Malignant Potential—13 Years' Experience. Clin. Exp. Obstet. Gynecol. 2022, 49(10), 234 DOI: 10.31083/j.ceog4910234
2. WHO classification of mesenchymal tumours of the lower genital tract. Female Genital Tumours WHO Classification of Tumours, 5th ed., Vol.4. WHO Classification of Tumours Editorial Board. WORLD HEALTH ORGANIZATION. 2020; pp13.
3. Gupta M, Laury AL, Nucci MR, Quade BJ. Predictors of adverse outcome in uterine smooth muscle tumours of uncertain malignant potential (STUMP): a clinicopathological analysis of 22 cases with a proposal for the inclusion of additional histological parameters. Histopathology 2018 73(2):284-298. doi: 10.1111/his.13515.
4. Smooth muscle tumour of uncertain malignant potential of the uterine corpus. Female Genital Tumours WHO Classification of Tumours, 5th ed., Vol.4. WHO Classification of Tumours Editorial Board. WORLD HEALTH ORGANIZATION. 2020; pp279-280.
5. Nishikawa S, Hayashi T, Amano Y, Yaegashi N, Abiko K, Konishi I. Characteristic of Concurrent Uterine Lipoleiomyoma and Hemangioma by Algorithm of Candidate Biomarkers for Uterine Mesenchymal Tumor. Diagnostics (Basel). 2022 Oct 12;12(10):2468. doi: 10.3390/diagnostics12102468.